Prosecution Insights
Last updated: April 19, 2026
Application No. 18/356,975

Programming of Neurostimulation Therapy

Non-Final OA §102
Filed
Jul 21, 2023
Examiner
FAIRCHILD, MALLIKA DIPAYAN
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Saluda Medical Pty Ltd.
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
To Grant
98%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
641 granted / 807 resolved
+9.4% vs TC avg
Strong +18% interview lift
Without
With
+18.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
39 currently pending
Career history
846
Total Applications
across all art units

Statute-Specific Performance

§101
8.1%
-31.9% vs TC avg
§103
35.4%
-4.6% vs TC avg
§102
22.8%
-17.2% vs TC avg
§112
21.2%
-18.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 807 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I (Claims 1-7) in the reply filed on 10/30/2025 is acknowledged. Claims 8-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on10/30/2025. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Annoni et al (U.S. Patent Application Publication Number: US 2020/0030035 A1, hereinafter “Annoni”). Regarding claims 1 and 6, Annoni teaches a neurostimulation system and an automated method of controllably delivering a neural stimulus to a patient comprising (e.g. Abstract, [0056]) comprising: a neuromodulation device (e.g. Figs.1-3, [0055], [0056]: patient can be evaluated after the patient has been implanted and is receiving SCS therapy) for controllably delivering neural stimuli, the neuromodulation device comprising: a plurality of implantable electrodes (e.g. 16 Fig.1) a stimulus source (e.g. 10 Fig.1, [0004]) configured to deliver neural stimuli via one or more of the implantable electrodes to a neural pathway of a patient; and a control unit configured to control the stimulus source to deliver each neural stimulus according to one or more stimulus parameters (e.g. [0004]-[008]); a headset (e.g. 420, Fig.4, [0041], [0056]) configured to be worn by the patient and to display a virtual object to the patient; one or more sensors configured to perceive a gesture of the patient (i.e. motion sensor e.g. 418 Fig. 10, [0042], [0043: motion sensor 418 to monitor movements of the patient's head or other body parts, one or more accelerometers or gyroscopes one or more of which may similarly be mounted to the headset 420 or worn by the patient.); and an external computing device (i.e. CP system 200’ e.g. Fig. 4, [0041]-[0043]) comprising a processor in communication with the neuromodulation device, the headset, and the one or more sensors, the processor being configured to: instruct the control unit to control the stimulus source to deliver a neural stimulus according to the one or more stimulus parameters (e.g. 604 Fig. 6, [0056], [0058]); transmit the virtual object to the headset for display to the patient (e.g. 606 Fig. 6 [0048]: a virtual environment may depict objects moving toward the patient and may prompt the patient to attempt to dodge the objects, may prompt the patient to mimic an activity that is being performed by the person that is depicted in the virtual environment (Note: the virtual object is a virtual person depicted in the virtual environment as taught by Annoni. Applicant’s originally filed specification in paragraph [0083] also states that the patient’s body may be rendered as a virtual object referred to as an “avatar”), [0057]: patient is fitted with a headset and performs certain tasks, [0059]: virtual environment is presented to the patient via the headset); receive information indicative of a gesture of the patient from the one or more sensors (e.g.606 Fig. 6 [0059]: virtual environment is presented to the patient via the headset and physiological data is received from the sensors at the CP system 200’, [0061]); and convert the information indicative of the gesture to a manipulation of the virtual object (e.g. [0061]: The virtual environment may utilize motion sensor data to present an image of the patient's movements as the patient attempts to mimic the activities that are being performed by the person that is depicted in the virtual environment). Regarding claims 2 and 7, Annoni teaches the virtual object is a virtual control object (e.g. [0048]: a virtual environment may depict objects moving toward the patient and may prompt the patient to attempt to dodge the objects, may prompt the patient to mimic an activity that is being performed by the person that is depicted in the virtual environment and so in Annoni the virtual person is considered as a virtual control object. Applicant’s originally filed specification in paragraph [0083] states that the patient’s body may be rendered as a virtual object referred to as an “avatar”), and the processor is further configured to: adjust a stimulus parameter of the one or more stimulus parameters based on the manipulation of the virtual control object; and instruct the control unit to control the stimulus source to deliver a neural stimulus according to the adjusted stimulus parameter (e.g. abstract: Stimulation settings for already-implanted patients may be adjusted while presenting a virtual or augmented environment to the patient, with objective measurements being determined for each stimulation setting which can then be used to determine optimal stimulation settings, [0063]: optimal stimulation settings associated with the highest therapeutic efficacy score are determined and communicated to the patient's neurostimulator.) Regarding claim 3, Annoni teaches that the processor is further configured to transmit the adjusted stimulus parameter to the neuromodulation device (e.g. [0063]: after the optimal stimulation settings are determined, they may be communicated to the patient's neurostimulator). Regarding claim 4, Annoni teaches the virtual object is a virtual human body and the processor is further configured to: convert the manipulation of the virtual human body to feedback about a sensation experienced by the patient in response to the neural stimuli being delivered by the stimulus source (e.g. [0060]: images of pain and stimulation may be presented on an avatar or another image of a person, and the images may be adjusted as the stimulation settings and the physiological data change). Regarding claim 5, Annoni teaches the processor is further configured to: determine one or more therapy parameters based on the feedback ([0060]: images of pain and stimulation may be presented on an avatar or another image of a person, and the images may be adjusted as the stimulation settings and the physiological data change); and transmit the one or more therapy parameters to the neuromodulation device (e.g. [0063]: after the optimal stimulation settings are determined, they may be communicated to the patient's neurostimulator). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MALLIKA DIPAYAN FAIRCHILD whose telephone number is (571)270-7043. The examiner can normally be reached Monday- Friday 8 am-5pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, BENJAMIN KLEIN can be reached at 571-270-5213. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MALLIKA D FAIRCHILD/Primary Examiner, Art Unit 3792
Read full office action

Prosecution Timeline

Jul 21, 2023
Application Filed
Nov 24, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599758
INTRAVASCULAR BLOOD PUMPS, MOTORS, AND FLUID CONTROL
2y 5m to grant Granted Apr 14, 2026
Patent 12594419
IMPLANTABLE MEDICAL DEVICE LEAD WITH MODULAR ELECTRODE
2y 5m to grant Granted Apr 07, 2026
Patent 12589234
INTRAVASCULAR BLOOD PUMPS
2y 5m to grant Granted Mar 31, 2026
Patent 12582826
Intra-Body Network System
2y 5m to grant Granted Mar 24, 2026
Patent 12576272
ENGAGEMENT COMPONENT SELECTION FOR CONTROL OF BIO-PSYCHIATRIC THERAPEUTIC TRAJECTORY (BTT)
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
98%
With Interview (+18.5%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 807 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month